{"id":"active-comparator-olaparib-tablets","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Anemia"},{"rate":"25-35","effect":"Nausea"},{"rate":"25-35","effect":"Fatigue"},{"rate":"15-25","effect":"Vomiting"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"20-30","effect":"Thrombocytopenia"},{"rate":"15-25","effect":"Leukopenia"},{"rate":"10-15","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PARP inhibitors block the repair of single-strand DNA breaks. In cells with BRCA1/2 mutations (deficient in homologous recombination repair), this leads to accumulation of DNA damage and synthetic lethality. Olaparib is effective in cancers with homologous recombination deficiency, including BRCA-mutant and other HRD-positive tumors.","oneSentence":"Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:13.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"BRCA-mutant metastatic breast cancer"},{"name":"BRCA-mutant ovarian cancer"},{"name":"BRCA-mutant pancreatic cancer"},{"name":"Homologous recombination deficiency-positive ovarian cancer (maintenance therapy)"},{"name":"Castration-resistant prostate cancer with HRD"}]},"trialDetails":[{"nctId":"NCT04742075","phase":"PHASE2","title":"Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2021-12-15","conditions":"Ovarian Cancer","enrollment":188},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT03106987","phase":"PHASE3","title":"A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-06-08","conditions":"Epithelial Ovarian Cancer","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Olaparib tablets"],"phase":"phase_3","status":"active","brandName":"Active Comparator: Olaparib tablets","genericName":"Active Comparator: Olaparib tablets","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors. Used for BRCA-mutant metastatic breast cancer, BRCA-mutant ovarian cancer, BRCA-mutant pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}